Underwater transparent silicon dioxide nanofiber substrate as well as preparation method of substrate and application of substrate to capture of circulating tumor cells

Abstract

The invention discloses an underwater transparent silicon dioxide nanofiber substrate as well as a preparation method of the substrate and application of the substrate to capture of circulating tumor cells. The preparation method of the substrate comprises the following steps: coating the surface of the substrate with a hydrolyzed tetraethoxy polymer solution by virtue of an electrospinning technique, then carrying out heat preservation by a drying box for further hydrolyzing; and finally burning the substrate at the high temperature to obtain the underwater transparent silicon dioxide nanofiber substrate; the substrate can be used for enriching and detecting circulating tumor cells after being further modified by a biochemistry surface antibody. The substrate has the characteristics of being high in efficiency of capturing the circulating tumor cells and high sensitivity and can be applied to clinical diagnosis of patients with cancer; meanwhile, the tumor cells captured by the substrate are high in activity; the substrate can be used for monitoring in real time and providing relevant information such as cellular morphology and has potential significance to the subsequent research of the tumor cells.

Description

technical field

[0001] The invention relates to the technical fields of functional materials, biomedical materials and nanomaterials, in particular to a method for preparing an underwater transparent silica nanofiber substrate and its use for the enrichment and detection of circulating tumor cells. Background technique

[0002] Circulating tumor cells, referred to as CTCs. It refers to the release of tumor cells from the primary tumor or metastases into the peripheral blood circulation due to spontaneous or diagnostic and therapeutic operations, forming circulating tumor cells. As a result, more tumors grow in organs farther away from the lesion, which is the main reason for the vast majority of malignant tumor patients to have distant metastasis and recurrence after surgery. In 1869, Thomas Ashworth first observed CTCs in a patient with metastatic cancer, and they speculated that the recognition of cells from circulating tumor cells found in the blood was likely responsibl...

Images